Company Profile
iCAD, Inc. Stock Price, News & Analysis
- Ticker:
- ICAD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for ICAD.
Company overview
Business overview
iCAD is a medical imaging and cancer-detection company focused on AI-enabled breast health and workflow software. Its business sits at the intersection of imaging, detection, and software.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, iCAD sits in medtech and diagnostics.
Business Model Characteristics
The company depends on product adoption, imaging workflow integration, and the monetization of its cancer-detection platform.
Position Within the Biotechnology Landscape
iCAD is outside biotech and belongs to the imaging and diagnostics layer.
Future catalysts
iCAD’s catalysts are ProFound AI adoption and breast-cancer detection workflow growth. The market will care about whether AI mammography keeps translating into durable clinical usage.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does iCAD, Inc. do?
iCAD is a medical imaging and cancer-detection company focused on AI-enabled breast health and workflow software. Its business sits at the intersection of imaging, detection, and software.
On which exchange is ICAD stock listed?
iCAD, Inc. (ICAD) is associated with NASDAQ, United States, Biopharma.
What is AI-enabled?
iCAD is a medical imaging and cancer-detection company focused on AI-enabled breast health and workflow software.
Which conditions is iCAD, Inc. targeting with AI-enabled?
iCAD, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does iCAD, Inc. describe recent progress with AI-enabled?
iCAD’s catalysts are ProFound AI adoption and breast-cancer detection workflow growth. The market will care about whether AI mammography keeps translating into durable clinical usage.
What is ProFound?
iCAD’s catalysts are ProFound AI adoption and breast-cancer detection workflow growth.
What should investors watch for with ProFound?
iCAD’s catalysts are ProFound AI adoption and breast-cancer detection workflow growth.
What future catalysts are investors watching for iCAD, Inc.?
iCAD’s catalysts are ProFound AI adoption and breast-cancer detection workflow growth. The market will care about whether AI mammography keeps translating into durable clinical usage.